Introduction of NAFLD and NASH
Nonalcoholic fatty liver disease (NAFLD) is defined as lipid-deposit accumulation in the hepatocytes, which is not due to excessive alcohol use. NAFLD encompasses a spectrum of diseases ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), which in its most severe form can lead to liver fibrosis, cirrhosis, and hepatocellular carcinoma. The NAFLD disorder has a prevalence of 15–20% in the general population and 76–90% in the obese. It is estimated that more than 1/3 of population worldwide will be risk in NAFLD, which is significantly exceeding an incidence of Hepatitis B, Hepatitis C and Alcoholic Liver Disease. NAFLD is now the most common disease of Liver.
Innovative Candidate Compounds for NASH treatment
ABP-6016 is a novel drug candidate for NASH treatment with a remarkable potency and very well tolerance in mice. It shows excellent efficacy in various NASH animal models by significantly relieving fatty degeneration of liver, reducing inflammatory reaction, anti-oxidant effect and etc. Low toxicity and good tolerance are shown in pre-clinical study. It is expected to be a new generation of innovative medicine for NASH treatment.